Alternative Treatment Utilization Before Hysterectomy for Benign Gynecologic Conditions at a Large Integrated Health System

• Published in: Journal of minimally invasive gynecology Vol. 26; no. 5; pp. 847 - 855
• Main Authors: Nguyen, Nancy T., Merchant, Maqdooda, Ritterman Weintraub, Miranda L., Salyer, Chelsea, Poceta, Joanna, Diaz, Lucero, Zaritsky, Eve F.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-07-2019
• Subjects: Adult; Alternative treatment; Benign hysterectomy; California - epidemiology; Delivery of Health Care, Integrated; Endometrial Ablation Techniques - methods; Endometriosis - surgery; Female; Humans; Hysterectomy - methods; Hysterectomy - statistics & numerical data; Hysteroscopy; Laparoscopy; Levonorgestrel - therapeutic use; Medroxyprogesterone - therapeutic use; Middle Aged; Myoma - surgery; Myomas; Pelvic Pain - surgery; Retrospective Studies; Social Class; Uterine Artery Embolization - methods; Uterine Diseases - surgery; Uterine Diseases - therapy; Uterine Myomectomy - methods; California; Benign hysterectomy; Myomas; Alternative treatment
• ISSN: 1553-4650; 1553-4669
• DOI: 10.1016/j.jmig.2018.08.013

To investigate rates of utilization of alternative treatments before hysterectomy for benign gynecologic indications within a large integrated health care system.
Retrospective cohort study of patients who underwent hysterectomies for benign gynecologic conditions between 2012 and 2014 (Canadian Task Force classification II-2).
Kaiser Permanente Northern California, a community-based integrated health system.
Women who underwent hysterectomy for a benign gynecologic condition between 2012 and 2014.
From an eligible cohort of 6892 patients who underwent hysterectomy, a stratified random sample of 1050 patients were selected for chart review. Stratification was based on the proportion of indications for hysterectomy.
The primary outcome was the use of alternative treatments before hysterectomy. Alternative treatments included oral hormone treatment, leuprolide, medroxyprogesterone intramuscular injections, a levonorgestrel intrauterine device, hormonal subdermal implants, endometrial ablation, uterine artery embolization, hysteroscopy, and myomectomy. Of the 1050 charts reviewed, 979 (93.2%) met the criteria for inclusion in this study. The predominant indication for hysterectomy was symptomatic myomas (54.4%), followed by abnormal uterine bleeding (29.0%), endometriosis (5.8%), pelvic pain (3.1%), dysmenorrhea (3.4%), and other (4.3%). The major routes of hysterectomy were laparoscopy (68.7%) and vaginal hysterectomy (13.4%). Before hysterectomy, 81.2% of patients tried at least 1 type of alternative treatment (33.8% with 1 treatment and 47.4% with at least 2 treatments), and 99.3% of patients were counseled regarding alternative treatments. Compared with younger women age <40 years, women age 45 to 49 years were less likely to use alternative treatments before hysterectomy (adjusted odds ratio, 0.41; 95% confidence interval, 0.21–0.76). There were no variations in treatment rates by socioeconomic status or between major racial and ethnic groups. The final pathological analysis identified myomas as the most common pathology (n = 637; 65.1%); 96 patients (9.8%) had normal uterine pathology.
More than 80% of patients received alternative treatments before undergoing hysterectomy for a benign gynecologic condition. Additional investigation is warranted to assess alternative treatment use as it relates to preventing unnecessary hysterectomies.